The tertiary C797S mutation in the EGFR tyrosine kinase domain disrupts osimertinib binding, driving resistance in NSCLC. We designed a series of novel diaminopyrimidine derivatives to establish the i
Despite the clinical success of tropomyosin receptor kinases (TRKs) inhibitors in NTRK fusion–positive cancers, prolonged administration has resulted in acquired resistance, particularly xDFG mutation
Histone deacetylase 8 (HDAC8) has emerged as promising therapeutic target for several malignancies. In this study, we developed two series of cereblon (CRBN)-recruiting proteolysis-targeting chimeras
Global Oncology Based In-vivo CRO Market Report 2024 comes with the extensive industry analysis of development components, patterns, flows and sizes. The report also calculates present and past market
